SGLT-2 inhibition by empagliflozin has no effect on experimental arterial thrombosis in a murine model of low-grade inflammation.
Luca LiberaleSimon KralerYustina M PuspitasariNicole R BonettiAlexander AkhmedovStefano MinistriniFabrizio MontecuccoNikolaus MarxMichael LehrkeNiels Ulrik K HartmannJürg H BeerFlorian A WenzlFrancesco PaneniThomas F LüscherGiovanni G CamiciPublished in: Cardiovascular research (2022)
SGLT-2 inhibition by empagliflozin does not impact experimental arterial thrombus formation, neither under BSL conditions nor during sustained low-grade inflammation, and has no impact on proxies of thrombotic/fibrinolytic activity in patients with ASCVD. The beneficial pleiotropic effects of empagliflozin are likely independent of pathways mediating arterial thrombosis.